Figure 3From: [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodesOverall survival. The overall survival rates are shown for all patients (n = 26). The 2 and 3 year survival rates were 94.4% and 82.6%.Back to article page